Barclays Maintains Underweight on Inspire Medical Systems, Lowers Price Target to $62
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Barclays analyst Christopher Pasquale maintains Inspire Medical Systems (NYSE:INSP) with a Underweight and lowers the price target from $65 to $62.
Barclays analyst Christopher Pasquale maintains Inspire Medical Systems (NYSE:INSP) with a Underweight and lowers the price target from $65 to $62.